Slide 1: Investor Presentation ASX cover letter
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 29 August 2024 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentati
Slide 2: Investor presentation: FY24 Full Year Results
For personal use only Investor presentation FY24 Full Year Results August 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited.
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Our mission
Our mission For personal use only To improve patient outcomes by setting new standards of care in fluid and body composition management. 3
Slide 5: ImpediMed: market leader in BIS
ImpediMed: market leader in BIS For personal use only ImpediMed offers bioimpedance spectroscopy (BIS) to assess and monitor the fluid status and tissue composition in patients. Our primary focus is breast cancer-related lymphoedema (BCRL), to reduce its devastating quality-of-life burden and avoida
Slide 6: Agenda
For personal use only Agenda FY24 highlights Financials Strategy and outlook 5
Slide 7: FY24 highlights
For personal use only FY24 highlights 6
Slide 8: FY24 Full-Year Results highlights
Core business revenue and ARR improving, overall revenues down due to cessation of Astra Zeneca clinical trial FY24 Full-Year Results For personal use only Total SOZO Core SOZO Core Number of patient revenue1 Business2 revenue Business ARR tests conducted $10.3 million $9.7 million $11.0 million 250
Slide 9: SOZO Core Business growth driven by US up 14%
SOZO Core Business growth driven by US up 14% Global revenue by category Global revenue by geography For personal use only 11.3 11.3 10.6 10.3 10.6 10.3 2.0 0.1 2.0 0.1 0.5 0.9 3.3 0.8 3.3 1.0 FY24 SOZO Core Business 0.7 1.1 revenue up 14% vs. FY23. A $ millions A $ millions 9.7 9.3 US business 90%
Slide 10: ARR is up 18% vs. FY23
ARR is up 18% vs. FY23, and continues to show long term growth SOZO Core Business ARR1 For personal use only 22% 11.0 3-year CAGR2 10.1 9.3 ARR up 18% vs. FY23 ($9.3m) 8.2 7.3 6.7 6.1 A$ millions FY21 H2 FY22 H1 FY22 H2 FY23 H1 FY23 H2 FY24 H1 FY24 H2 1.Annual Recurring Revenue (ARR) represents the
Slide 11: Patient testing grew 24% as a 3-year CAGR
Patient testing grew 24% as a 3-year CAGR SOZO patient tests (000s) For personal use only 24% 3-year CAGR1 18% growth vs. FY23 154 126 An important driver of renewals 92 70 40 96 17 85 62 72 47 32 8 2 FY18 FY19 FY20 FY21 FY22 FY23 FY24 New Follow up 1.Compound Annual Growth Rate (based on annual tot
Slide 12: FY24 unit sales down 16% on FY23
FY24 unit sales down 16% on FY23, with growth emerging in Q4 in key US market Number of units sold globally Number of US units by quarter: FY24 For personal use only 23 71 19 64 57 56 13 13 25 32 25 20 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 46 36 32 32 Renewed commercial strategy with focus on US key state
Slide 13: Global installed base grew 9% versus FY23
Global installed base grew 9% versus FY23 Installed base units1 For personal use only Up 9% Global vs FY23 U.S. Rest of World 1,083 1,041 997 56 57 933 71 64 Up 8% Up 9% vs FY23 vs FY23 547 570 489 528 36 494 513 32 469 46 20 32 444 25 25 32 FY23 H1 FY23 H2 FY24 H1 FY24 H2 FY23 H1 FY23 H2 FY24 H1 FY
Slide 14: Return to growth in TCV
We are gaining momentum with a return to growth in TCV SOZO Core Business Quarterly Total Contract Value (TCV1) For personal use only 3.8 3.5 3.4 3.2 2.8 Focus on commercial execution 2.2 2.2 with urgency A$ millions 1.6 Gaining momentum FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q
Slide 15: Financials
For personal use only Financials 14
Slide 16: P&L – FY24
P&L – FY24 $million Change For personal use only Total revenue down $1.0 million or 9% vs FY24 FY23 $m FY23 due to loss of clinical revenue. SOZO core business revenue 9.7 8.5 1.2 14% SOZO Core Business revenue up $1.2 Legacy/other revenue 0.5 0.8 (0.3) -38% million or 14% vs FY23. Clinical reve
Slide 17: Cash flow closely managed through cost efficiencies
Cash flow closely managed through cost efficiencies, primarily staffing $million For personal use only FY24 FY23 Change Net cash used in operating activities of $17.8 million Net cash (used in) includes: operating activities (17.8) (18.0) 0.2 • Cash receipts from customers of $11.5 million (FY23: $1
Slide 18: Strategy and outlook
For personal use only Strategy and outlook 17
Slide 19: Building a sustainable business
Building a sustainable business For personal use only New Executive Team and new Board Commercial focus on lead generation and conversion for targeted US BCRL customers Prioritize key US states – high reimbursement, high population More efficient cost management Building a pathway to future growth 1
Slide 20: Immediate priority is focused US BCRL execution
Immediate priority is focused sales, marketing and clinical execution in US BCRL opportunity ImpediMed 12-month priorities with new Board and Executive Team For personal use only Next 12 months: Execute towards break even July 2025 Next 1-2 years: Building a pathway to future growth GOAL 1 GOAL 2 GO
Slide 21: Focus for FY25
Focus for FY25 For personal use only Our priority is to support clinicians to provide top-tier guideline driven care to prevent breast cancer-related lymphoedema. SOZO is both an investment in patient outcomes and a financially sustainable decision, where tests are reimbursed. Positive momentum is c
Slide 22: For personal use only
impedimed’ Ajuo asn jeuosiad 4104 21